YY2201
YY2201 is a highly potent and selective ATR inhibitor with an IC50 of 8 nM. YY2201 shows >200-fold more selective for ATR than mTOR. YY2201 inhibits tumor progression in broad-spectrum cancer types (such as lung cancer) [1].
Product Specifications
UNSPSC
12352005
Target
ATM/ATR
Related Pathways
Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Cancer
Smiles
CC1=NN(C2=CC=CN=C2)C(C)=C1C3=CC(N4C[C@@H](CC5)O[C@@H]5C4)=NC6=C(C7=CC=NN7)C=NN36.OC(/C=C/C(O)=O)=O
Molecular Formula
C29H29N9O5
Molecular Weight
583.60
References & Citations
[1]Wu M, et al. Discovery of the Clinical Candidate YY2201 as a Highly Potent and Selective ATR Inhibitor. J Med Chem. 2025 Mar 13;68 (5) :5292-5311.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6372949-01 0.1 mL
CD23 (Low Affinity Immunoglobulin epsilon Fc Receptor, BLAST-2, C-type Lectin Domain Family 4 Member J, Fc-epsilon-RII, Immunoglobulin E-binding Factor, Lymphocyte IgE Receptor, FCER2, CD23A, CLEC4J, FCE2, IGEBF) (AP)
Ask
View Details